91 related articles for article (PubMed ID: 20449550)
1. [IQWiG's methods for the cost-benefit assessment : Comparison with an international reference scenario].
Schwalm A; Danner M; Seidl A; Volz F; Dintsios CM; Gerber A
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jun; 53(6):615-22. PubMed ID: 20449550
[TBL] [Abstract][Full Text] [Related]
2. [Comments by the Working Group for Methods of Economic Evaluation in Health Care (AG MEG) to IQWiG's Draft Guidelines "Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System"].
Krauth C; John J; Aidelsburger P; Brüggenjürgen B; Hansmeier T; Hessel F; Kohlmann T; Moock J; Rothgang H; Schweikert B; Seitz R; Wasem J;
Gesundheitswesen; 2008 Jun; 70(6):e1-16. PubMed ID: 18661452
[TBL] [Abstract][Full Text] [Related]
3. [Should IQWiG revise its methods of cost-effectiveness analysis in order to comply with more widely accepted health economical evaluation standards?].
Lübbe W
Dtsch Med Wochenschr; 2010 Mar; 135(12):582-5. PubMed ID: 20234995
[TBL] [Abstract][Full Text] [Related]
4. [Drug assessment: IQWiG, G-BA, and an international comparison].
Glaeske G
Internist (Berl); 2016 Jan; 57(1):94-101. PubMed ID: 26502888
[TBL] [Abstract][Full Text] [Related]
5. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
6. The value of health care--a matter of discussion in Germany.
Porzsolt F; Ackermann M; Amelung V
BMC Health Serv Res; 2007 Jan; 7():1. PubMed ID: 17199886
[TBL] [Abstract][Full Text] [Related]
7. [Decision-analytical modelling of costs per QALY in the context of the German Social Law].
Rogowski WH; Landauer M; John J
Gesundheitswesen; 2009 Nov; 71(11):739-50. PubMed ID: 19551622
[TBL] [Abstract][Full Text] [Related]
8. The Probabilistic Efficiency Frontier: A Framework for Cost-Effectiveness Analysis in Germany Put into Practice for Hepatitis C Treatment Options.
Mühlbacher AC; Sadler A
Value Health; 2017 Feb; 20(2):266-272. PubMed ID: 28237207
[TBL] [Abstract][Full Text] [Related]
9. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
10. [Promotion of general health and scientific literacy via consumer and patient information: the role of the IQWiG].
Bastian H; Kaiser T; Matschewsky S
Z Arztl Fortbild Qualitatssich; 2005; 99(6):379-85. PubMed ID: 16121654
[TBL] [Abstract][Full Text] [Related]
11. Drug pricing and control of health expenditures: a comparison between a proportional decision rule and a cost-per-QALY rule.
Gandjour A
Int J Health Plann Manage; 2015; 30(4):395-402. PubMed ID: 24789123
[TBL] [Abstract][Full Text] [Related]
12. Sins of omission and obfuscation: IQWIG's guidelines on economic evaluation methods.
Sculpher M; Claxton K
Health Econ; 2010 Oct; 19(10):1132-6. PubMed ID: 20662107
[No Abstract] [Full Text] [Related]
13. A theoretical and empirical investigation into the willingness-to-pay function for new innovative drugs by Germany's health technology assessment agency (IQWiG).
Gandjour A
Health Serv Manage Res; 2013 Nov; 26(4):103-9. PubMed ID: 25595007
[TBL] [Abstract][Full Text] [Related]
14. [In which categories should we think in when spending public health resources: value for money or rights for money?].
Lübbe W
Z Evid Fortbild Qual Gesundhwes; 2010; 104(3):202-8. PubMed ID: 20608248
[TBL] [Abstract][Full Text] [Related]
15. [Evidence based medicine: theoretical bases and current misuse for cost cutting in the public health sector].
Pfützner A; Forst T; März W; Jacob S
Internist (Berl); 2007 Apr; 48(4):426-35. PubMed ID: 17364168
[TBL] [Abstract][Full Text] [Related]
16. [On the necessity of benefit assessments across all indications].
Breyer F
Z Evid Fortbild Qual Gesundhwes; 2010; 104(3):209-14. PubMed ID: 20608249
[TBL] [Abstract][Full Text] [Related]
17. International experience with comparative effectiveness research: case studies from England/Wales and Germany.
Bridges JF; Cohen JP; Grist PG; Mühlbacher AC
Adv Health Econ Health Serv Res; 2010; 22():29-50. PubMed ID: 20575227
[TBL] [Abstract][Full Text] [Related]
18. The efficiency-frontier approach for health economic evaluation versus cost-effectiveness thresholds and internal reference pricing: combining the best of both worlds?
Sandmann FG; Mostardt S; Lhachimi SK; Gerber-Grote A
Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):475-486. PubMed ID: 29979895
[TBL] [Abstract][Full Text] [Related]
19. Effects of the National Institute for Health and Clinical Excellence's technology appraisals on prescribing and net ingredient costs of drugs in the National Health Service in England.
Dietrich ES
Int J Technol Assess Health Care; 2009 Jul; 25(3):262-71. PubMed ID: 19619344
[TBL] [Abstract][Full Text] [Related]
20. Cost Recommendation under Uncertainty in IQWiG's Efficiency Frontier Framework.
Corro Ramos I; Lhachimi SK; Gerber-Grote A; Al MJ
Med Decis Making; 2017 Feb; 37(2):162-172. PubMed ID: 27005521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
